Who owns VTRS
987 institutions reported holding VTRS for 2026Q1, together 84% of the company, more than the 983 a quarter earlier.
987
Institutions reporting a position · as of 2026Q1 · up from 983 the quarter before
- Shares held by institutions
- 986.9M
Shares held by institutions · 84% of the company · long US equity positions only, as reported on Form 13F
- Reported value
- $13.3B
Reported value · at 2026-03-31 prices, not today's
- Top 5 holders
- 36%
Top 5 holders · of the whole company, between five filers
Details›
- Reporting quarter2026-03-31
- 2026Q1
- Quarters on record
- 22
- New positions
- 119
- Positions exited
- 121
- Added to
- 305
- Reduced
- 282
- Top 10 holdersof the company
- 48%
| Quarter | Filers | Shares | Reported value |
|---|---|---|---|
| 2026Q1 | 987 | 986.9M | $13.3B |
| 2025Q4 | 983 | 974.5M | $12.1B |
| 2025Q3 | 955 | 956.6M | $9.48B |
| 2025Q2 | 961 | 971.8M | $8.69B |
| 2025Q1 | 992 | 968.7M | $8.44B |
| 2024Q4 | 1,025 | 993.7M | $12.4B |
| 2024Q3 | 987 | 950.0M | $11.0B |
| 2024Q2 | 982 | 973.6M | $10.3B |
| 2024Q1 | 991 | 959.7M | $11.5B |
| 2023Q4 | 1,002 | 955.0M | $10.3B |
| 2023Q3 | 948 | 936.1M | $9.23B |
| 2023Q2 | 971 | 929.7M | $9.28B |
| 2023Q1 | 977 | 913.2M | $8.78B |
| 2022Q4 | 1,003 | 926.5M | $10.3B |
| 2022Q3 | 968 | 916.6M | $7.82B |
| 2022Q2 | 996 | 896.2M | $9.39B |
| Holder | Shares | % of company | Value |
|---|---|---|---|
| VANGUARD GROUP INC | 139.4M | 12% | $1.88B |
| BlackRock Inc. | 84.4M | 7.2% | $1.14B |
| Davis Selected Advisers | 78.2M | 6.7% | $1.06B |
| PRICE T ROWE ASSOCIATES INC /MD/ | 65.9M | 5.6% | $890M |
| STATE STREET CORP | 52.2M | 4.4% | $706M |
| DIMENSIONAL FUND ADVISORS LP | 38.3M | 3.3% | $518M |
| Rubric Capital Management LP | 33.5M | 2.9% | $453M |
| GEODE CAPITAL MANAGEMENT LLC | 31.8M | 2.7% | $430M |
| Invesco Ltd. | 22.0M | 1.9% | $297M |
| DEERFIELD MANAGEMENT CO /NY | 20.2M | 1.7% | $273M |
SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.
reading the register…
Drug Manufacturers - Specialty & Generic
Ranks #7 of 28 by Smart Score